Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms

Chemotherapy paclitaxel yields significant reductions in tumor burden in the majority of advanced non-small cell lung cancer (NSCLC) patients. However, acquired resistance limits its clinical use. Here we demonstrated that the histone deacetylase (HDAC) was activated in paclitaxel-resistant NSCLC ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, L, Li, H, Ren, Y, Zou, S, Fang, W, Jiang, X, Jia, L, Li, M, Liu, X, Yuan, X, Chen, G, Yang, J, Wu, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816165/
https://www.ncbi.nlm.nih.gov/pubmed/26794658
http://dx.doi.org/10.1038/cddis.2015.328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816165/
https://www.ncbi.nlm.nih.gov/pubmed/26794658
http://dx.doi.org/10.1038/cddis.2015.328

Ejemplares similares